Advertising
Showing 1 to 15 of 207 entries
PAST TOP PICK
(A Top Pick Jan 10/20, Down 3%) Stock price popped on news of therapeutic pill. We're in a medical emergency, yet drug space is languishing, quite extraordinary. Lots of value. Model price of $146, 90% upside. Yield is 3.4%
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly This $195 billion marketcap global drug manufacturer has just received FDA emergency approval for an oral COVID-19 treatment and is reiterated as a TOP PICK. Japan just committed to 200,000 doses of the new pill. Trading at 11x forward earnings, compared with its peers at 19x, it is good value here. It pays an excellent dividend, backed by payout ratio under 50% of forward cash flow. We recommend trailing up the stop (from $65) to $70, looking to achieve $92.50 -- upside potential of 19%. Yield 3.59% (Analysts’ price target is $92.31)
biotechnology / pharmaceutical

Unlock the Weekly Buzzing Stocks

Become a member Or, Sign In
TOP PICK
The pandemic casued a decline in the use of their drugs in hospitals. This should return eventually. The new anti-covid pill is also a short-term win. Social media mentions are up 467% in the last 24 hours.
biotechnology / pharmaceutical
TOP PICK
A laggard, as pandemic caused a decline in its drugs used in hospitals. This demand will eventually return. Demand for new anti-Covid pill will be a short-term winner. Decently valued. Yield is 3.23%. (Analysts’ price target is $94.82)
biotechnology / pharmaceutical
BUY
Today, Merck may have beaten Covid. That's why the market rallied today. Today had nothing to do with inflation or supply shortages. If you take this pill after testing positive for Covid, the pill can save you and crush symptoms. Merck can produce 10 million course of these pills by year's end. No wonder Merck shares surged nearly 9% today. Industrials and delivery stocks could be worth buying now.
biotechnology / pharmaceutical
BUY

MRK vs. ABT Both are great companies. ABT is the leading supplier of glasswork to the medical industry. Merck has incredible products as a global pharmaceutical company. You could buy either one.

biotechnology / pharmaceutical
WATCH
They have an analyst meeting on Monday. Watch that, because they reported ugly numbers earlier this week.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly MRK returns as a TOP PICK. Trading at 17 times earnings, compared with its peers at 40x it is good value here. It pays an excellent dividend, backed by payout ratio of only 50% of cash flow. We would buy it here with a stop-loss at $65, looking to achieve $96 -- upside potential of 23%. Yield 3.36% (Analysts’ price target is $96.33)
biotechnology / pharmaceutical
DON'T BUY

Like BMY, nobody wants these drug stocks now. The reopening trade is a headwind. The economy will reopen, so investors think they don't need a drink stock, no matter how well that stock is performing.

biotechnology / pharmaceutical
BUY
It's a bellwhether pharamceutical, but he doesn't like this space because drug patents constantly expire under given patent law. Merck is getting interesting, partially because of valuation around 12x PE. Also, because their franchise drug is an oncology drug that doesn't come off patent until 2026. It pays a good dividend. It's become more interesting because the PE has declined.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Jan 30/20, Down 1%) Still likes. Continues to buy. Discount to other big pharma. Cancer drugs are very high margin. Pandemic has spurred pharma sales. Will benefit as life returns to normal. Yield is 3.1%.
biotechnology / pharmaceutical
SELL

All big pharmas have been treading water. Patent legislation has left them with a leaky boat. He's gravitated toward the bio-pharmas. His favourite in that space is AbbVie, as it's good on fundamentals and financials, inexpensive, very fine dividend, great cashflow generator.

biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Sep 29/20, Down 5.9%)Stockchase Research Editor: Michael O'Reilly We are recommending to cover MRK as it has violated our stop-loss. We are going to look for better opportunities.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Oct 24/19, Down 2%) Healthcare is a resilient sector, not cyclical. Strong in oncology space. Pandemic has crimped pharma sales, especially from hospitals. Shares are cheap, 9% earnings growth rate, dividend over 3%.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Jul 17/19, Down 4%) Still likes this diversified large-cap biopharma. Has a great diabetes franchise, though little growth, but they rely on an immunotherapy franchise (a cancer treatment)--they've done great execution here over the past 6 years.
biotechnology / pharmaceutical
Showing 1 to 15 of 207 entries

Merck & Company(MRK-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 5

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 6

Stockchase rating for Merck & Company is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Merck & Company(MRK-N) Frequently Asked Questions

What is Merck & Company stock symbol?

Merck & Company is a American stock, trading under the symbol MRK-N on the New York Stock Exchange (MRK). It is usually referred to as NYSE:MRK or MRK-N

Is Merck & Company a buy or a sell?

In the last year, 6 stock analysts published opinions about MRK-N. 5 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Merck & Company.

Is Merck & Company a good investment or a top pick?

Merck & Company was recommended as a Top Pick by on . Read the latest stock experts ratings for Merck & Company.

Why is Merck & Company stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Merck & Company worth watching?

6 stock analysts on Stockchase covered Merck & Company In the last year. It is a trending stock that is worth watching.

What is Merck & Company stock price?

On 2022-01-27, Merck & Company (MRK-N) stock closed at a price of $80.57.